Hiroki Sano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroki Sano has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ryoji Yanai
Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan
4 shared publications Yoshinori Mitamura
Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
3 shared publications- Yoshinori Mitamura
Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
3 shared publications Daisuke Nagasato
1 shared publicationFumiko Murao
Department of Ophthalmology Institute of Biomedical Sciences Tokushima University Graduate School Tokushima Japan
1 shared publicationHirotaka Kondo
1 shared publication
Latest Publications
- 12 September 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 530-537
Cumulative Clinical Risk Factor Burden Stratifies the Need for Additional Retinal Intervention After Laser Retinopexy for Retinal Tears
- 12 September 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 292, 530-537
Cumulative Clinical Risk Factor Burden Stratifies the Need for Additional Retinal Intervention After Laser Retinopexy for Retinal Tears
- Open Access
- 21 July 2026
- Published by Elsevier in Ophthalmology Retina
Development and Validation of Simple Clinical and OCT-Based Prognostic Scores for Visual Outcomes in Branch Retinal Vein Occlusion
- 21 July 2026
- Published by Elsevier in Ophthalmology Retina
Open AccessDevelopment and Validation of Simple Clinical and OCT-Based Prognostic Scores for Visual Outcomes in Branch Retinal Vein Occlusion
- Open Access
- 29 April 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e952247
Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report
Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report - Article abstract #952247
- 29 April 2026
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 27, e952247
Open AccessHemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report
Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report - Article abstract #952247
- Open Access
- 25 November 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e950495
Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report
BACKGROUND Branch retinal vein occlusion (BRVO) is a common cause of vision loss in older adults, and cystoid macular edema (CME) is its most frequent vision-threatening complication. Depending on severity, vitreomacular traction (VMT) is typically managed with observation or surgery. When CME develops during observation (e.g., in BRVO), the therapeutic approach becomes more complex. Anti-vascular endothelial growth factor (VEGF) therapy is a standard treatment for CME secondary to BRVO. Although full-thickness macular hole (FTMH) formation is rare, it has been reported in eyes with preexisting VMT, suggesting a contributory role for tractional forces. CASE REPORT A 72-year-old woman under observation for VMT developed BRVO with CME. Baseline optical coherence tomography revealed VMT, an epiretinal membrane, a lamellar macular hole, and a vertical hyperreflective line at the fovea resembling the "foveal crack sign". The patient received an intravitreal faricimab injection to achieve rapid edema resolution with fewer injections. CME improved; however, an FTMH subsequently developed, accompanied by a decline in best-corrected visual acuity to 20/33. The patient then underwent combined vitrectomy and cataract surgery, which achieved successful hole closure. CME recurred postoperatively but responded well to a second faricimab injection, resulting in visual recovery to 20/22. CONCLUSIONS FTMH may develop after anti-VEGF therapy in eyes with preexisting VMT. This appears to be the first reported case following faricimab treatment for BRVO-associated CME, underscoring the need for careful pretreatment evaluation of the vitreoretinal interface and awareness of potential tractional complications. Individualized treatment strategies may help reduce such risks and improve outcomes.
- 25 November 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e950495
Open AccessFull-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report
BACKGROUND Branch retinal vein occlusion (BRVO) is a common cause of vision loss in older adults, and cystoid macular edema (CME) is its most frequent vision-threatening complication. Depending on severity, vitreomacular traction (VMT) is typically managed with observation or surgery. When CME develops during observation (e.g., in BRVO), the therapeutic approach becomes more complex. Anti-vascular endothelial growth factor (VEGF) therapy is a standard treatment for CME secondary to BRVO. Although full-thickness macular hole (FTMH) formation is rare, it has been reported in eyes with preexisting VMT, suggesting a contributory role for tractional forces. CASE REPORT A 72-year-old woman under observation for VMT developed BRVO with CME. Baseline optical coherence tomography revealed VMT, an epiretinal membrane, a lamellar macular hole, and a vertical hyperreflective line at the fovea resembling the "foveal crack sign". The patient received an intravitreal faricimab injection to achieve rapid edema resolution with fewer injections. CME improved; however, an FTMH subsequently developed, accompanied by a decline in best-corrected visual acuity to 20/33. The patient then underwent combined vitrectomy and cataract surgery, which achieved successful hole closure. CME recurred postoperatively but responded well to a second faricimab injection, resulting in visual recovery to 20/22. CONCLUSIONS FTMH may develop after anti-VEGF therapy in eyes with preexisting VMT. This appears to be the first reported case following faricimab treatment for BRVO-associated CME, underscoring the need for careful pretreatment evaluation of the vitreoretinal interface and awareness of potential tractional complications. Individualized treatment strategies may help reduce such risks and improve outcomes.
- 8 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (1) , 259-261
Cataract Surgery Under General Anesthesia in Older Adults With Advanced Cataracts and Dementia: Visual Acuity and Visual Function Outcomes
- 8 October 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (1) , 259-261
Cataract Surgery Under General Anesthesia in Older Adults With Advanced Cataracts and Dementia: Visual Acuity and Visual Function Outcomes
- Open Access
- 24 October 2021
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 13 (4) , 628-637
Ocular expression of cyclin‐dependent kinase 5 in patients with proliferative diabetic retinopathy
Aims/Introduction Inhibition of peroxisome proliferator-activated receptor gamma (PPARγ) phosphorylation mediated by cyclin-dependent kinase 5 (Cdk5) is one of the main mechanisms of action of antidiabetic drugs. In this study, we analyzed the ocular expression and activation of Cdk5 in patients with proliferative diabetic retinopathy (PDR). Materials and Methods The concentrations of PPARγ, Cdk5, and its activating subunit (p35) were determined in the vitreous body of 24 PDR and 63 control eyes by enzyme-linked immunosorbent assay. In addition, the mRNA and protein expression levels of PPARγ, Cdk5, and p35 were measured in proliferative neovascular membranes from seven PDR eyes and non-neovascular epiretinal membranes from five control eyes by quantitative real-time polymerase chain reaction and immunohistochemical analysis. Results PPARγ, Cdk5, and p35 concentrations in the vitreous body were significantly higher in the PDR group compared with the control group. There was also a positive significant correlation of Cdk5 with PPARγ and p35 in the PDR group. Furthermore, the mRNA expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes were significantly higher in the PDR group compared with the control group. Immunostaining revealed increased protein expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes in the PDR group compared with the control group. Conclusions Cdk5 activation is involved in PDR pathogenesis via PPARγ expression, and inhibition of Cdk5-mediated PPARγ phosphorylation may be a new therapeutic target for treatment of PDR.
- 24 October 2021
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 13 (4) , 628-637
Open AccessOcular expression of cyclin‐dependent kinase 5 in patients with proliferative diabetic retinopathy
Aims/Introduction Inhibition of peroxisome proliferator-activated receptor gamma (PPARγ) phosphorylation mediated by cyclin-dependent kinase 5 (Cdk5) is one of the main mechanisms of action of antidiabetic drugs. In this study, we analyzed the ocular expression and activation of Cdk5 in patients with proliferative diabetic retinopathy (PDR). Materials and Methods The concentrations of PPARγ, Cdk5, and its activating subunit (p35) were determined in the vitreous body of 24 PDR and 63 control eyes by enzyme-linked immunosorbent assay. In addition, the mRNA and protein expression levels of PPARγ, Cdk5, and p35 were measured in proliferative neovascular membranes from seven PDR eyes and non-neovascular epiretinal membranes from five control eyes by quantitative real-time polymerase chain reaction and immunohistochemical analysis. Results PPARγ, Cdk5, and p35 concentrations in the vitreous body were significantly higher in the PDR group compared with the control group. There was also a positive significant correlation of Cdk5 with PPARγ and p35 in the PDR group. Furthermore, the mRNA expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes were significantly higher in the PDR group compared with the control group. Immunostaining revealed increased protein expression levels of PPARγ, Cdk5, and p35 in proliferative neovascular membranes in the PDR group compared with the control group. Conclusions Cdk5 activation is involved in PDR pathogenesis via PPARγ expression, and inhibition of Cdk5-mediated PPARγ phosphorylation may be a new therapeutic target for treatment of PDR.